CA-MAANA
29.3.2021 16:02:10 CEST | Business Wire | Press release
Airbus Commercial and Maana today announced Airbus Cognitive Platform (“AIRKOG”) that is capable of answering any domain-specific question.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005119/en/
“As a transformational platform, AIRKOG is helping us to drive improvements at Airbus Commercial,” said Florent Bouix, AIRKOG Platform Manager for Big Data products service line at Airbus. “We provide solutions to thousands of employees with an increasing number of intelligent applications in engineering, procurement, logistics, quality, program management, as well as rapid analysis for plant and final assembly line improvements.”
Using AIRKOG platform capabilities, Airbus consolidates data from tens of different systems; identifies and establishes a vast number of relations and correlations, implement computations and run analysis across multiple operational domains; all on a single platform.
“Thanks to AIRKOG, we achieved multi-million Euro cost savings per year at various areas,” Mr. Bouix stated “for example:
- Managing complex process related to new parts introduction due to aircraft changes for new Head of Version (involving engineering, sourcing, ordering, and manufacturing),
- Supporting the margin reviews or costs reduction of some aircraft options,
- Mastering electrical harnesses configuration changes and reallocation by providing multivariate analysis to avoid scrapping in a complex manufacturing organization with multiple plants.”
AIRKOG started in 2017 as a proof of concept for use of knowledge graph technology to reduce time spent by Airbus engineers and technicians searching for information. AIRKOG moved to pilot phase in 2018, and into production in 2019. After two years running in production at scale, Airbus Commercial and Maana extended their partnership for another three years for 2021-2023.
“AIRKOG is an intelligent platform, like its consumer-facing cousins Siri and Alexa,” said Babur Ozden, Founder and CEO of Maana. “However, it answers far more difficult questions regarding many complex aspects of making, maintaining, and repairing aircraft.”
“Thanks to AIRKOG platform and the computational knowledge graph at its core, we reduced costs by 20% - 30% and lead-time for analysis by 30% - 75% on our digitalization platform” said Marc Monties, WideBody digitalization plateau leader at Airbus.
About Airbus Commercial Aircraft
Airbus is a leading aircraft manufacturer whose customer focus, commercial know-how, technological leadership and manufacturing efficiency have propelled it to the forefront of the aviation and air transport industries. The company’s mission is to provide jetliners that are best-suited to the market's needs and to support them with the highest quality of service.
About Maana
Maana organizes human expertise, enterprise knowhow and industrial data into digital knowledge to assist subject matter experts at critical operation affecting the global economy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin6.8.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress disorder (PTSD). The trial, titled "Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression," or PIVOT, reflects VA’s commitment to pursuing innovative solutions for veterans who have not responded to existing treatments. Compass will donate the study drug - COMP360, a synthetic, proprietary pharmaceutical-grade formulation of psilocybin optimized for stability and purity. Compass will support the education and training of the investigators and their training team through the provision of training
Great Britain Leads Europe’s FMCG Inflation as NIQ Launches New Inflation Barometer6.8.2026 09:00:00 CEST | Press release
NIQ (NYSE: NIQ) today launches its new EU5 FMCG Inflation Barometer - a monthly tracker across five Western Europe markets – France, Great Britain, Germany, Italy and Spain – designed to help retailers, manufacturers and the media understand how inflation is evolving across Europe’s largest grocery markets and how shoppers are responding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806579111/en/ EU5 CPG Inflation slows to +1.1% The first edition of the Barometer reveals that while inflation across Europe’s FMCG sector remains relatively contained overall, significant differences persist between countries. Key findings include: Great Britain recorded the highest FMCG inflation across the EU5 at +2.3%1, above the European average of +1.1%. France and Italy reported the lowest inflation at -0.4% and +0.6% retrospectively, highlighting the uneven inflationary landscape across Europe's major economies. The monthly Barometer
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom